Chest diseases Hospital Hematology Patient care plans
|
|
- Gillian Glenn
- 5 years ago
- Views:
Transcription
1 Chest diseases Hospital Hematology Patient care plans Hematology Service in CDH in a consultation service for management of hematologic complications of cardiology/ cardiac surgery. Primary hematologic diseases are not diagnosed or treated in CDH. Patients are admitted in CDH for having a procedure or surgery which may need clearance from the hematology side. Evaluating the patient preoperatively is performed by the Surgeon/Anesthesiologist in charge. Hematologist play a role when the pre-operative hematology laboratory tests shows abnormalities which can affect patient outcome. Chronic cases ( e.g. chronic anemia, chronic thrombocytopenia are referred to their area hospital for detailed diagnosis, treatment and after correction sent to CDH cleared for the procedure/ surgery ) Patient who are candidates for urgent procedures/ surgeries & have hematologic problem are referred to the hematologist. Hematologist should asses the patient by history taking, clinical examination and further testing according to the results of the pre-operative tests. In emergency situation, where the patient requires urgent procedures, hematologist can be contacted by phone if required. Assessment of anemia: Ø Preoperative anemia should be properly diagnosed & managed in relation to the degree of urgency of the operation. Ø Anemia diagnosis and management is mainly based on classification according to RBCs indices and morphology on peripheral smear examination into : Microcytic hypochromic anemia which is mainly either iron deficiency anemia or Thalassemia. Normocytic normochromic anaemia which is mostly either hemorrhagic, hemolytic or secondary to chronic disease,rarely due to double deficiency. Macrocytic anemia mostly secondary to hypoproliferative marrow whether primary or secondry to vitaminb12 &/or Folate deficiency.
2 anemia care plan Urgent procedure Elective procedure Permissible HB HB 8-10gm/dl Type of anemia Threshold>/=10g/dl PRBCs Transfusion According to MCV,MCH MCV,MCH N MCV,MCH MCV Iron profile,serum ferritin & HB electrophoresis Smear Retics B12 Folate smear- Retics Thalassemia trait Iron deficiency DAT IAT RFT Iron supplements TFT &GI Consult Collagen screen LFT treatment is for the primary disease replacement therapy
3 Ø Preoperative sickling test & G6PD are usually requested by the surgeon in the last OPD visit, Positive tests should be confirmed by a further confirmatory & quantitative test. Ø Partial exchange transfusion is advised in sickle cell anemia to reduce HB S to < 30 % & keep HB >10 gm/dl. Ø Avoiding drugs that deteriorates the condition is clearly documented, with requesting substitute. Assessment of thrombocytopenia: Minimun platelet count can be accepted as a permissible ceiteria differs according to the procedure needed as follows in table 1 : Table1: permissive platelet count in relation to the procedure Procedure name Cardiac surgery Coronary angio/pci Central line placement Endoscopy ( without biopsy) Endoscopy ( biopsy) Lumber puncture Gastroscopy (biopsy) Permissive platelet count /Ul ( practice) /Ul /Ul /Ul /Ul /Ul /Ul If the surgery/ procedure is elective, patient has to be referred to area hospital for further diagnosis& treatment. If the surgery is urgent patients can be sent to OR ( considering that the other screening coagulation parameters are normal) after ensuring adequate platelet stock for probable transfusion. All thrombocytopenic patients,who had previous exposure to unfractionated heparin or Clexane HIT should be ruled out by clinical assessment ( 4T score ) or HIT serology. Special consideration is also given to postoperative drugs needed like postoperative antiplatelet drugs needed. Thrombocytopenia is a frequent complication that occurs to the hospitalized patients & specially tocdh patients. Treating physician usually sends a written request to the on call hematologist for proper diagnosis & further management. The hematologist follows the thrombocytopenia care plan as follows:
4 Thrombocytopenia care plan False ( Platelet clumps ) Request another properly collected samples True Thrombocytopenia EDTA R/O Bad sampling Citrate R/O EDTA induced clumps Check smear for Blast or immature cells Usually at admission Fragmented RBCs (v. rare) shift to left toxic changes Search for organomegaly Refer to KCC Order : Haptoglobin LFT Urine urobilinogen Septic screen Hypersegmented neutrophils & macrocytosis serum B12 & red cell folate and replacement therapy Ø If all are negative, drug history is reviewed & suspected drug is to be discontinued.
5 If HIT is suspected, 4T score calculated & heparin is discontinued & replaced with non heparin anticoagulant if a high score is obtained (6-8) Ø If all are negative, presentation is acute & patient had received blood within the last 2 weeks, Posttransfusion purpura is suspected, tested for & if confirmed I/V Ig & corticosteroids are to be started if platelet count is less than /ml. Ø Chronic cases are usually diagnosed and treated in their area hospitals & when admitted in CDH, hematologist only follow up the treatment plan scheduled for him. Assessment of erthrocytosis: Ø Patients with a raised venous haematocrit (Hct) (>52 % in males, >48% females) are referred to hematology. The recommendation will be : proper hydration, D/C diuretics ( after cardiologist/nephro approval). Ø If still not corrected : venesection is advised to reach a target of 45%. The volume removed should be commensurate with the patient s size and comorbidities. Ø Venesection is done by the ward nurse under supervision of the treating physician. Ø Patients with a congenital cyanotic heart disease, develop secondary polycythemia to their cyanosis, the haematocrit may reach levels greater than 65% and symptoms of hyperviscosity usually develop at higher cutoff. Venesection is usually advised on bases of symptoms together with the hematocrit level. Assessment of Neutropenia/neutrophelia: Cases of neutropenia ( ANC < 500/UL) to diagnose the cause of neutropenia & advices to cover the procedure by antibiotic if a benign chronic cause is suspected after reviewing the peripheral smear. Cases of leucocytosis ( WBCs >30.000/UL ) after smear review, if a hematologic malignancy is suspected, patient is to be referred to KCC and cleared from his hematologic oncologist. Assessment coagulation condition: Ideally, INR & aptt ratio are to be within the range of 1:0 to 1.3(each).In urgent conditions if INR is >1.4 & aptt >40 seconds, FFp transfusion in the dose of 15 ml /kg is given 4 hours before surgery & reassess pt/inr & aptt just before surgery. In more elective condition, the prolongation of the clotting time should be investigated, cause defined & treated. Clearance for urgent procedures :
6 There are many bedside procedures done during the patient stay in CDH, some of them need hematologic clearance. The decision varies when the patient is on anticoagulant/antiplatelet drugs, where he has to be evaluated bearing in the benefits & and risks of stopping/continuing the drug as follows :( considering the risk of the procedure is the bleeding risk, while the risk of the condition is the thrombotic risk that necessitates the anticoagulant/antiplatelet therapy) 1. Low risk procedure in a patient with high or low risk condition : a) Warfarin is kept, INR is kept therapeutic ( less than 3) b) Full dose antiplatelet therapy( Plavix) to be continued. 2. High risk procedures, low risk conditions ( bridging unnecessary): a) Warfarin to be stopped 5 days before the procedure ( INR should be less than 1.5) b) Warfarin to be restarted on the evening of the procedure in the usual daily dose. c) Plavix to be stopped 7 days before the procedure. d) Aspirin to be continued if already prescribed. If the patient was not on aspirin, aspirin can cover the period of plavix discontinuation. 3. High risk procedure,high risk condition ( bridging required) a) Warfarin to be stopped 5 days before the procedure. b) Bridging with LMWH (therapeutic dose ) to be started 2 days after discontinuing warfarin. Omit LMWH on the day of the procedure. c) Warfarin is to be restarted on the night of the procedure in the same dose. LMWH is to be continued till INR is therapeutic. d) Plavix is to be discontinued 7 days befor the procedure ( after cardiologist approval, if 6 months post DES placement/ or six weeks of BMS placement). Plavix is to be restarted the day after the procedure. Low risk procedures ( bleeding risk less than 1%) Central Venous line placement, IVC filter,tooth extraction, upper & lower GI endoscopy ( with biopsy),swan ganz catheter, arterial line, IABP, peritoneal aspiration,pericardiocentesis,tracheostomy,coronary angiography Ø Warfarin is kept with a target INR of 2.5. Ø Full-dose antiplatelet therapy (e.g., Plavix) to be continued through these procedures. High risk procedures ( bleeding risk more than 1%) Cardiac catherterization,pci, cardiac ablation,pacemaker placement, Transbronchial biopsy, arterial puncture, Lumber puncture, Ø low individual risk for thrombosis, anticoagulation can be interrupted without bridging therapy (heparin). Ø Most patients at high individual risk of thrombosis should receive bridging anticoagulation therapy.
7 Bridging therapy ( For patients used to take warfarin) is strongly recommended for people with: DVT or PE within the past 3 months or severe thrombophilia. Mechanical mitral valves. "Old" design mechanical aortic valves (caged-ball or tilting-disk design, i.e., nonbileaflet). Any mechanical valve with a history of stroke or transient ischemic attack, Non-valvular atrial fibrillation with a CHADS2 score 4 or greater. history of stroke or TIA, or cardiac thrombus. Low risk condition ( for thrombosis) 1.Metal valave in the Aortic position. 2.Tissue heart valve. 3. AF without valve disease 4.DVT after first 3 months of therapy 5.thromboembolism 1.Warfarin to be stopped 5 days before the procedure, INR should reach 1.5 before the procedure 2.Warfarin to be restarted within 24 hours High risk condition 1.Metal valve in the mitral position. 2.AF and any type of prothetic valve 3.AF with Mitral stenosis. 4.AF withvalvular heart disease ( surgically corrected or not) 5.AF with any of: thromboembolic disease, LVF ( EF less than 35%) hypercoagulable disease, DM, HTN, age more than 75 years 6.Recently Placed Coronary stent ( less than 1 year) 7. Acute Coronary Syndrome. 8. Mechanical valve with H/O thromboembolic disease. 9.Recent conversion of AF 10. First 3 months of treating DVT/PE 11. thrombophelic syndrome 1, Warfarin to be stopped 5 days before the procedure. 2. When INR less than 2, LMWH to be started 3. LMWH to be omitted4-6 hours before the procedure. 4. LMWH to be restarted after the procedure. 5.Warfarin to be started at the evening of the procedure. 3.LMWH to be continued till warfarin is
8 therapeutic. Patients on NOAC ( Dabigatran or rivaroxaban ) usually have non valvular AF, drug should be discontinued 2-3 days before the procedure/ surgery & restarted 2-3 days after the procedure / surgery, without bridging. Low dose LMWH( 0.4 mgod ) can be used postop till reinitiation of the drug. References: 1. Transfusion guidelines : when to transfuse : 2013 ; Szczepiorkowski &Dunbar, Transfusion Medicine ( ASH Guidelines) 2. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients : 2013 : Retter et al.,british Journal of Hematology,160, Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis:2005: British Journal of Haematology, 130, UpToDate 2014: Clinical & laboratory aspects of platelet transfusion therapy: 5. Red Blood cell transfusion : A Clinical Practice guidelines from AABB : 2012: Carson et al., Annals of Internal Medicine,49-58 (American College of Physicians). 6. Recommendation for the transfusion of red cells :2009: Liumbruno etal., Blood Transfus :7: Evidence based Platelet Transfusion :2007, Slichter, Transfusion Medicine : Australian Medical Association guidelines on Patient examination Revised The ACCP 9th edition clinical practice guidelines for prevention and treatment of venous thromboembolism,perioperative management of antithrombotic therapy 2012
Chest diseases Hospital Laboratory Hematology standard Practice guidelines
Chest diseases Hospital Laboratory Hematology standard Practice guidelines Title Clearance criteria for adult surgical procedures SOP Code Policy Owner Hematology Unit Section Hematology Prepared By Dr.
More informationOral anti-thrombotic therapy-management in patients requiring endoscopy
Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More information4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationPatients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures
This is an official Northern Trust policy and should not be edited in any way Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures Reference Number: NHSCT/11/454
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationChest diseases Hospital Laboratory Hematology Practice guidelines
Chest diseases Hospital Laboratory Hematology Practice guidelines Title RBCs transfusion in Adults SOP Code Policy Owner Hematology Unit Section Hematology Prepared By Dr. Taher Ahmed Abdelhameed Issuing
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı
ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationt. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.
Name or Policy: Policy Number: 3364-133-116 Department: Approving Officer: Responsible Agent: cope: x Management of Anticoagulation with Invasive Procedures Pharmacy Chief Operating Officer Director of
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationPerioperative Management of Anticoagulation
Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationPreoperative Management of Patients Receiving Antithrombotics
Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing
More informationTaking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss
Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss Joanne Eddington, MN, FNP, AOCN Providence Oncology and Hematology Care Clinic - Eastside Blood Cell Abnormalities Abnormalities
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationTo Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin
To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin Omprakash Pansara, MD Brian Kline, MD St. Joseph s Health Family Medicine Residency Program, Syracuse, NY Case 75yr old male, who
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More informationHaematology dilemma s to refer or not to refer?
Haematology dilemma s to refer or not to refer? NWL Pathology GP Study Day Dr Fatts Chowdhury Consultant Haematologist in Transfusion Medicine NHS Blood and Transplant Senior Honorary Clinical Lecturer
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationThe Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery. Alex C. Spyropoulos MD, FACP, FCCP, FRCPC
The Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery Alex C. Spyropoulos MD, FACP, FCCP, FRCPC Professor of Medicine Hofstra Northwell School of Medicine
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationPerioperative Anticoagulation Management
Perioperative Anticoagulation Management ACP Delaware Chapter Scientific Meeting Feb 9, 2019 Andrew Dunn, MD, MPH, MACP Chief, Division of Hospital Medicine Mount Sinai Health System, NY DISCLOSURES Desai
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationEAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY
EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent
More informationGuidelines for Anticoagulation in Paediatric Cardiac Patients
Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe
More informationAnticoagulation Transitions: Perioperative Care
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical Associates Four Questions for each Consultation 1.
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management
Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management Assessment Tools and Suggested Management for the Patient on Antithrombotics Undergoing a Screening-Related Colonoscopy Version
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationInterpreting the CBC. Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired
Interpreting the CBC Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired The CBC 3 Cell Lines RBCs WBCs Platelets Assess general health Make
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationPeri-Procedural Management of Antithrombotic Agents
u Peri-Procedural Management of Antithrombotic Agents An Integrated Care Pathway of the Collaborative Care Network Subject Matter Experts: Will Maxted, MD Veronica Kerner, PharmD Pathway Custodian: Pat
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationon Anti-coagulants -- Is It Safe? And When to Stop?
Endoscopy for Your Patient on Anti-coagulants -- Is It Safe? And When to Stop? John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationPeriprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline
Periprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline A. Scope (disease/condition, treatment, clinical specialty) 1. Adult patients undergoing a procedure or surgery
More informationDiagnosis & Management of Heparin-Induced Thrombocytopenia
Diagnosis & Management of Heparin-Induced Thrombocytopenia An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric Tseng
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationThings to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC
Things to never miss in the office Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC Presenter Disclosure Faculty / Speaker s name: Brett Houston / Leonard Minuk Relationships with commercial
More informationPerioperative management of Anticoagulant and Antiplatelet medication GL067
Perioperative management of Anticoagulant and Antiplatelet medication GL067 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair, Anaesthetics Clinical November
More informationPerioperative Management of Warfarin Interruption
Perioperative Management of Warfarin Interruption Victoria Lambert, PharmD, CACP Medication Management Pharmacist William W. Backus Hospital Faculty Disclosures There are no actual or potential conflicts
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationEndoscopy and the Anticoagulated Patient
Endoscopy and the Anticoagulated Patient John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Objectives To accurately assess the risk
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationEvaluation of Anemia. Md. Shafiqul Bari Associate professor (Medicine) SOMC
Evaluation of Anemia Md. Shafiqul Bari Associate professor (Medicine) SOMC Definition Anemia is operationally defined as a reduction in one or more of the major RBC measurements Hemoglobin concentration
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationPCCN Review Hematology
PCCN Review Hematology Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Anemia Definition reduction in RBC concentration Causes iron deficiency
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationHeparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
More informationHEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS
1 of 6 Policy #: 800 (PLH-800-13) Initiated Date: 12/4/2002 Reviewed Date: 8/1/2016 Subject: HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS Approved by: Laboratory Director, Jerry Barker (electronic signature)
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationDr Calum Young Cardiologist Tauranga
Dr Calum Young Cardiologist Tauranga 8:30-9:25 WS #93: New Oral Anticoagulant Drugs and Management of AF 9:35-10:30 WS #105: New Oral Anticoagulant Drugs and Management of AF (Repeated) GPCME 2016: Anticoagulation
More informationWarfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin
Warfarin in Adults : Guidelines for the use of Document Type: Clinical Guideline Clinical Lead: Ian Neilly Author/s: Ian Neilly/Paul Barbieri Directorate: Haematology Approved by Haematology Specialty
More informationAntiplatelets in cardiac patients with suspected GI bleeding
Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding
More informationEdoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationRobert Moesinger MD--Moderator Joe Hansler MD--Surgery Justin Mansfield MD Internal Medicine Charles Ivester MD, PHD Pulmonology/Critical Care John
Robert Moesinger MD--Moderator Joe Hansler MD--Surgery Justin Mansfield MD Internal Medicine Charles Ivester MD, PHD Pulmonology/Critical Care John Lund MD--Cardiology This presentation has no commercial
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More information78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1) Gene Gulati PhD, SH(ASCP)
78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1) Gene Gulati PhD, SH(ASCP) 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 1600 Chicago,
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationUpdate in Perioperative Anticoagulation and Antiplatelet management
Update in Perioperative Anticoagulation and Antiplatelet management Grand Rounds October 31, 2014 Brooke Hall, MD Steve Kornfeld, MD Bruce McLellan, MD Nothing to disclose Objectives Describe the updates
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationPart 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks.
Part 1 examination Haematology: First paper Tuesday 20 March 2018 Candidates must answer all questions. Each question is worth a total of 25 marks. Time allowed: 3 hours Question 1: General Haematology
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs
More informationManagement of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More information